The Thai government announced, via the Thai Khu Fah Facebook page on 20 July, that three locally produced COVID-19 vaccines will be ready for administration by next year.
The first, CU-Cov19 (mRNA), is being developed in collaboration with Chulalongkorn University’s Faculty of Medicine and the University of Pennsylvania, and is currently in the human-trial phase.
The second, HXP-GPO Vac (inactivated), is developed by the Government Pharmaceutical Organization in collaboration with Mahidol University and the United States’ PATH Institute. It is also currently in the human-trial phase.
The last one, Baiya SARS-CoV-1 Vax 1, is developed from tobacco leaves by Baiya Phytopharm and Chulalongkorn University. This vaccine has been successfully tested on animals and will soon be tried out on humans.
The first, CU-Cov19 (mRNA), is being developed in collaboration with Chulalongkorn University’s Faculty of Medicine and the University of Pennsylvania, and is currently in the human-trial phase.
The second, HXP-GPO Vac (inactivated), is developed by the Government Pharmaceutical Organization in collaboration with Mahidol University and the United States’ PATH Institute. It is also currently in the human-trial phase.
The last one, Baiya SARS-CoV-1 Vax 1, is developed from tobacco leaves by Baiya Phytopharm and Chulalongkorn University. This vaccine has been successfully tested on animals and will soon be tried out on humans.
2 thoughts on “Three COVID-19 Vaccines Produced in Thailand Will Be Ready for Administration by Next Year”
Comments are closed.